MedTrace Logo

A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies

NCT00405743 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2013-09-18

No results posted yet for this study

Summary

Patients with refractory or relapsed hematologic malignancies will receive CP-4055 intravenously(IV) on Day 1-5 every three weeks until complete response or disease worsening/progressing

Conditions

Interventions

DRUG

CP-4055

CP-4055 Continuous IV infusion

DRUG

CP-4055

CP4055 2 and 4 hour IV infusion

Sponsors & Collaborators

  • Clavis Pharma

    lead INDUSTRY

Principal Investigators

  • Francis J Giles, MD · Institute for Drug Development (IDD), Cancer Therapy and Research Center, San Antonio, Texas, USA

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2009-05-31
Completion
2010-05-31

Countries

  • United States
  • France
  • Germany
  • Italy
  • Norway
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00405743 on ClinicalTrials.gov